LLY

1,136.74

+4.61%↑

JNJ

227.5

+1.33%↑

ABBV

222.33

+1.68%↑

UNH

395.67

+3.16%↑

MRK

119.04

+2.72%↑

LLY

1,136.74

+4.61%↑

JNJ

227.5

+1.33%↑

ABBV

222.33

+1.68%↑

UNH

395.67

+3.16%↑

MRK

119.04

+2.72%↑

LLY

1,136.74

+4.61%↑

JNJ

227.5

+1.33%↑

ABBV

222.33

+1.68%↑

UNH

395.67

+3.16%↑

MRK

119.04

+2.72%↑

LLY

1,136.74

+4.61%↑

JNJ

227.5

+1.33%↑

ABBV

222.33

+1.68%↑

UNH

395.67

+3.16%↑

MRK

119.04

+2.72%↑

LLY

1,136.74

+4.61%↑

JNJ

227.5

+1.33%↑

ABBV

222.33

+1.68%↑

UNH

395.67

+3.16%↑

MRK

119.04

+2.72%↑

Home・Listă Acțiuni・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Închisă

SectorSănătate

69.75 5.78

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

65.78

Maxim

70.12

Indicatori cheie
By Trading Economics
Venit	292M 150M
Vânzări	-75M 377M
P/E Medie Sector	23.909 49.888
EPS	1.221
Marjă de profit	39.832
Angajați	423
EBITDA	-63M 218M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+29.45% upside

Dividende
By Dow Jones
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	432M 8.1B
Deschiderea anterioară	63.97
Închiderea anterioară	69.75

Sentimentul știrilor

By Acuity

27%

73%

69 / 344 Clasament în Healthcare

Halozyme Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 iun. 2026, 23:22 UTC

Câștiguri

Principalele dinamici ale pieței

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 iun. 2026, 23:09 UTC

Acțiuni populare

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 iun. 2026, 20:51 UTC

Câștiguri

Costco Reports 15% Sales Growth in May

3 iun. 2026, 20:43 UTC

Câștiguri

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 iun. 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 iun. 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 iun. 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 iun. 2026, 23:15 UTC

Market Talk

Câștiguri

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 iun. 2026, 22:08 UTC

Acțiuni populare

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 iun. 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 iun. 2026, 21:18 UTC

Câștiguri

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 iun. 2026, 21:15 UTC

Câștiguri

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 iun. 2026, 21:13 UTC

Câștiguri

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 iun. 2026, 21:13 UTC

Câștiguri

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 iun. 2026, 21:12 UTC

Câștiguri

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 iun. 2026, 21:09 UTC

Câștiguri

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 iun. 2026, 21:03 UTC

Câștiguri

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 iun. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 iun. 2026, 20:43 UTC

Câștiguri

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 iun. 2026, 20:39 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 iun. 2026, 20:37 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 iun. 2026, 20:35 UTC

Câștiguri

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 iun. 2026, 20:21 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 iun. 2026, 20:17 UTC

Câștiguri

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 iun. 2026, 20:17 UTC

Câștiguri

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 iun. 2026, 20:15 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 iun. 2026, 20:15 UTC

Câștiguri

Broadcom 2Q Adj EPS $2.44 >AVGO

3 iun. 2026, 20:15 UTC

Câștiguri

Broadcom 2Q EPS $1.91 >AVGO

3 iun. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 iun. 2026, 20:15 UTC

Câștiguri

Broadcom 2Q Rev $22.19B >AVGO

Comparație

Modificare preț

Halozyme Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

29.45% sus

Prognoză pe 12 luni

Medie 85.8 USD 29.45%

Maxim 96 USD

Minim 70 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHalozyme Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor Halozyme Therapeutics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

69 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.